Indications |
Oral Peripheral vascular disease Adult: 10 mg tid. Maintenance: 5-10 mg tid. Max: Up to 60 mg daily in divided doses. Renal impairment: Reduce dose. Oral Mental deterioration associated with cerebrovascular insufficiency Adult: 10 mg tid. Maintenance: 5-10 mg tid. Max: Up to 60 mg daily in divided doses. Renal impairment: Reduce dose. Intramuscular Peripheral vascular disease Adult: 2-4 mg bid. Renal impairment: Reduce dose. Intramuscular Symptoms of mental deterioration associated with cerebrovascular insufficiency Adult: 2-4 mg bid. Renal impairment: Reduce dose. Intravenous Peripheral vascular disease Adult: 4-8 mg by slow IV infusion (over 30 min). Renal impairment: Reduce dose. Intravenous Symptoms of mental deterioration associated with cerebrovascular insufficiency Adult: 4-8 mg by slow IV infusion (over 30 min). Renal impairment: Reduce dose. Reconstitution: Dilute in 250 ml saline solution. |
Warnings / Precautions |
Porphyria. Pregnancy. |
Adverse Reactions |
GI disturbances; hypotension (especially after parenteral admin). Hot flushes, malaise, hyperacidity, nausea, diarrhoea, dizziness, somnolence. |
Drug Interactions |
May potentiate action of antihypertensives. May increase cardiac depressant effects of propranolol. See Below for More nicergoline Drug Interactions |
Mechanism of Actions |
Nicergoline is an ergot derivative. It has α-adrenergic blocking activity and produces vasodilatation. Onset: 1-1.5 hr (oral). Absorption: Rapidly absorbed from the GI tract (oral). Distribution: Protein-binding: 82-87%. Metabolism: Undergoes significant 1st-pass effect. Excretion: Via urine (80%), via faeces (20%). |
Administration |
Should be taken on an empty stomach. (Take on an empty stomach.) |
ATC Classification |
C04AE02 - nicergoline ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators. |
Available As |
|
Nicergoline
Post Review about Nicergoline Click here to cancel reply.
Nicergoline Containing Brands
Nicergoline is used in following diseases
Drug - Drug Interactions of Nicergoline
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.